C4 Therapeutics Inc (NASDAQ: CCCC)’s stock price has soared by 6.70 in relation to previous closing price of 6.79. Nevertheless, the company has seen a gain of 10.78% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-05 that CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis
Is It Worth Investing in C4 Therapeutics Inc (NASDAQ: CCCC) Right Now?
The 36-month beta value for CCCC is also noteworthy at 3.23. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CCCC is 57.88M, and at present, short sellers hold a 16.52% of that float. The average trading volume of CCCC on May 08, 2024 was 2.24M shares.
CCCC’s Market Performance
CCCC’s stock has seen a 10.78% increase for the week, with a -9.10% drop in the past month and a 31.49% gain in the past quarter. The volatility ratio for the week is 6.14%, and the volatility levels for the past 30 days are at 5.68% for C4 Therapeutics Inc The simple moving average for the last 20 days is 6.87% for CCCC’s stock, with a simple moving average of 52.54% for the last 200 days.
Analysts’ Opinion of CCCC
Many brokerage firms have already submitted their reports for CCCC stocks, with JP Morgan repeating the rating for CCCC by listing it as a “Neutral.” The predicted price for CCCC in the upcoming period, according to JP Morgan is $6 based on the research report published on January 29, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $12, previously predicting the price at $2. The rating they have provided for CCCC stocks is “Buy” according to the report published on December 13th, 2023.
Credit Suisse gave a rating of “Neutral” to CCCC, setting the target price at $10 in the report published on February 24th of the previous year.
CCCC Trading at -12.11% from the 50-Day Moving Average
After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.02% of loss for the given period.
Volatility was left at 5.68%, however, over the last 30 days, the volatility rate increased by 6.14%, as shares sank -6.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.31% lower at present.
During the last 5 trading sessions, CCCC rose by +9.86%, which changed the moving average for the period of 200-days by +92.63% in comparison to the 20-day moving average, which settled at $6.75. In addition, C4 Therapeutics Inc saw 28.23% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CCCC
Current profitability levels for the company are sitting at:
- -7.94 for the present operating margin
- 0.67 for the gross margin
The net margin for C4 Therapeutics Inc stands at -7.42. The total capital return value is set at -0.39. Equity return is now at value -49.50, with -32.82 for asset returns.
Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.32. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 68.23.
Currently, EBITDA for the company is -131.29 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 27.93. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.34.
Conclusion
In summary, C4 Therapeutics Inc (CCCC) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
